Clinical Trial Update: Phase 2 Study of Oral K201 for Prevention of AF Recurrence [Phase 2]

View source ↗

Summary

This update reports termination of a Phase 2 study evaluating oral K201 for prevention of atrial fibrillation recurrence.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atrial Fibrillation

Drugs mentioned

• K201

Snippet

Sponsor: Sequel Pharmaceuticals, Inc | Conditions: Atrial Fibrillation | Phase 2 | Status: TERMINATED